RxDoctor Payments Data

Sirna Musa, NP

Family · Jackson, MSNPI 1376034660

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 25 payments — averaging $50.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$444
  • Merck$158
  • Novo Nordisk$122
  • Viiv Healthcare Company$105
  • Boehringer Ingelheim$103
  • Theratechnologies Inc.$97
  • plus $224 from 5 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,759
Medicare patients
15
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala243$916,709
JulucaDolutegravir/Rilpivirine164$552,812
GenvoyaElviteg/Cob/Emtri/Tenof Alafen22$88,203
TivicayDolutegravir Sodium35$87,157
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$81,717
DovatoDolutegravir Sodium/Lamivudine29$77,554
TriumeqAbacavir/Dolutegravir/Lamivudi19$66,696
DescovyEmtricitabine/Tenofov Alafenam14$30,224
JardianceEmpagliflozin16$16,770
Albuterol Sulfate HfaAlbuterol Sulfate33$1,034
Atorvastatin Calcium163$897
Omeprazole36$313
Dicyclomine Hcl13$275
Losartan Potassium25$261
Potassium Chloride28$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$444$1,035,136279 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Triumeq$105$784,218247 claims
Boehringer IngelheimJardiance$103$16,77016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →